Surveillance of adverse events following immunisation in Australia annual report, 2022
DOI:
https://doi.org/10.33321/cdi.2025.49.043Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccineAbstract
This report summarises Australia’s spontaneous surveillance data for non-COVID-19 vaccine adverse events following immunisation (AEFI) for 2022, reported to the Therapeutic Goods Administration (TGA). National spontaneous (passive) surveillance data for coronavirus disease 2019 (COVID-19) vaccine AEFI reported to the TGA are analysed and discussed in a separate companion publication.
There were 3,642 AEFI reports for non-COVID-19 vaccines administered in 2022, representing an annual AEFI reporting rate of 14.0 per 100,000 population, compared with 13.4 per 100,000 population in 2021. This very small increase in the AEFI reporting rate in 2022 could potentially be related to the combination of several factors: a gradual return to pre-pandemic AEFI reporting patterns; new vaccination programs in response to outbreaks of emergent vaccine preventable diseases (Japanese encephalitis and mpox); and a change in the reporting activities of pharmaceutical sponsors. AEFI reporting rates for individual vaccines in 2022 were similar to 2021.
Downloads
References
Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization (WHO). Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Geneva: CIOMS; 2012. Available from: https://www.who.int/publications/m/item/9789290360834.
Therapeutic Goods Administration (TGA). Reporting adverse events. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing, TGA; 2024. [Accessed during 2024.] Available from: https://www.tga.gov.au/safety/reporting-problems/reporting-adverse-events.
World Health Organization (WHO). Global manual on surveillance of adverse events following immunization: 2016 update. Geneva: WHO; 31 May 2016. Available from: https://www.who.int/publications/i/item/9789241507769.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell Q Rep. 2003;27(3):307–23.
Glover C, Deng L, Larter C, Brogan C, Richardson O, Huang YA et al. Surveillance of adverse events following immunisation in Australia annual report, 2021. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.1.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in Japanese encephalitis vaccination practice in Australia. Sydney: Sydney Children’s Hospital Network, NCIRS; March 2024. [Accessed during 2024.] Available from: https://ncirs.org.au/sites/default/files/2024-03/Japanese%20encephalitis_History%20table.pdf.
Valeri M, Durrani S, Tran C, Chiu C, Macartney KK, Giles ML et al. ATAGI 2023 annual statement on immunisation. Commun Dis Intell (2018). 2023; 47 doi: https://doi.org/10.33321/cdi.2023.47.42.
Australian Government Federal Register of Legislation. Therapeutic Goods Act 1989. [Legislation.] Canberra: Australian Government; 2024. [Accessed during 2024.] Available from: https://www.legislation.gov.au/C2004A03952/latest/versions.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell Q Rep. 2004;28(3):324–38.
O’Moore M, Jones B, Hickie M, Glover C, Deng L, Huang Y et al. National pharmacovigilance of seasonal influenza vaccines in Australia. Med J Aust. 2024;221(4):178–81. doi: https://doi.org/10.5694/mja2.52381.
Huang YA, Larter C, Hickie M, O’Moore M, Jones B, Deng L et al. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2022. Commun Dis Intell (2018). 2025;49. doi: https://doi.org/10.33321/cdi.2025.49.044.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Introductory Guide MedDRA Version 26.1. Brussels: ICH; September 2023. Available from: https://admin.meddra.org/sites/default/files/guidance/file/intguide_26_1_English.pdf.
Medical Dictionary for Regulatory Activities (MedDRA). Standardised MedDRA Queries. [Webpage.] Herndon VA: MedDRA: 2023. [Accessed during 2024.] Available from: https://www.meddra.org/standardised-meddra-queries.
MedDRA. Introductory Guide for Standardised MedDRA Queries (SMQs) (Version 26.1). Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, MedDRA; September 2023. Available from: https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_26_1_English.pdf.
WHO. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019 update. Geneva: WHO; 16 April 2021. Available from: https://www.who.int/publications/i/item/9789241516990.
Australian Bureau of Statistics. National, state and territory population. Reference period: June 2022. [Webpage.] Canberra: Australian Bureau of Statistics; 15 December 2022. [Accessed during 2023.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/jun-2022.
Australian Government: Services Australia. Australian Immunisation Register. [Webpage.] Canberra: Services Australia; 2024. [Accessed during 2024.] Available from: https://www.servicesaustralia.gov.au/australian-immunisation-register.
Australian Government Department of Health, Disability and Ageing. Mandatory reporting of Japanese encephalitis virus vaccines to the Australian Immunisation Register began on 21 December 2022. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing; 13 January 2022. [Accessed during 2024.] Available from: https://www.health.gov.au/news/mandatory-reporting-of-japanese-encephalitis-virus-vaccines-to-the-australian-immunisation-register-began-on-21-december-2022.
Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual Immunisation Coverage Report 2022. Commun Dis Intell (2018). 2025;49. doi: https://doi.org/10.33321/cdi.2025.49.023.
R Core Team. R: A Language and Environment for Statistical Computing. [Application.] Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/.
TGA. Database of Adverse Event Notifications (DAEN). [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing, TGA; 2023. [Accessed during 2024.] Available from: https://www.tga.gov.au/safety/database-adverse-event-notifications-daen.
TGA. DAEN – medicines: Information for consumers. [Webpage.] Canberra: Australian Government Department of Health, Disability and Ageing, TGA; 2023. [Accessed during 2025.] Available from: https://www.tga.gov.au/resources/resource/reference-material/daen-medicines-information-consumers#what-the-tga-does-with-information-in-the-database.
European Medicines Agency (EMA). Imvanex: smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara). [Webpage.] Amsterdam: EMA; 2024. [Accessed during 2024.] Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex.
Weidenthaler H, Vidojkovic S, Martin BK, De Moerlooze L. Real-world safety data for MVA-BN: increased frequency of syncope following intradermal administration for immunization against mpox disease. Vaccine. 2024;42(22):126024. doi: https://doi.org/10.1016/j.vaccine.2024.05.072.
NCIRS. History of immunisation in Australia. [Webpage.] Sydney: Sydney Children’s Hospital Network, NCIRS; 2024.[Accessed during 2024.] Available from: https://ncirs.org.au/health-professionals/history-immunisation-australia.
Therapeutic Goods Administration - TGA. [‘Facebook’ social media post.] Facebook; 5 October 2021. Available from: https://www.facebook.com/TGAgovau/posts/pfbid0SUHvJqCSfi1tTNJTWjgVnasjVeDmgL6MzrSHPrH6M32zZXSFVn2rncDmjsaHNxBcl.
Therapeutic Goods Administration - TGA. [‘Facebook’ social media post.] Facebook; 1 March 2022. Available from: https://www.facebook.com/TGAgovau/posts/pfbid02t48T1Ft8zoetjAkvUt6o8mK7TqUt4bf3vfE1S6oagGPhc2W1swftEgCa1jtRTbC1l.
Australian Government Department of Health, Disability and Ageing. Australian Technical Advisory Group on Immunisation (ATAGI) Clinical Advice. Statement on the administration of seasonal influenza vaccines in 2022. Canberra: Australian Government Department of Health, Disability and Ageing; March 2022. [Accessed during 2024.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/02/atagi-advice-on-seasonal-influenza-vaccines-in-2022.pdf.
Australian Government Department of Health, Disability and Ageing. Vaccine safety in Australia AusVaxSafety – Summary report 2022. Canberra: Australian Government Department of Health, Disability and Ageing; 23 February 2024. Available from: https://www.health.gov.au/resources/publications/vaccine-safety-in-australia-ausvaxsafety-summary-report-2022.
Deng L, Lopez L, Glover C, et al. Short-term adverse events following immunization with modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for Mpox. JAMA. 2023;329(23):2091–4. doi: https://doi.org/10.1001/jama.2023.7683.
Shimabukuro T, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–405. doi: https://doi.org/10.1016/j.vaccine.2015.07.035.
Tuckerman J, Blyth CC, Beard FH, Danchin MH. COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR). Med J Aust. 2021;214(6):247–9. doi: https://doi.org/10.5694/mja2.50971.
Published
How to Cite
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
